Wort "Medical Technology" umgeben von Symbolen - Reagenzglas, Arzt, Bluttest, Diagramm

Our medical technology portfolio – extensive expertise for sustainable and profitable growth.

Fundamental changes in healthcare such as new regulations, falling reimbursement rates and the growing number of purchasing associations are making it increasingly difficult for medical technology companies to remain on a path of growth and profitability in a conventional manner. At the same time, new topics such as value-based care, personalized medicine, digitization and the associated consumerization offer unprecedented opportunities.

In order to adequately meet these challenges, medical technology companies must understand the mechanisms of their market as well as individual customer requirements holistically. In a dynamic market environment, strategies, solutions and organizational structures must be consistently evaluated and aligned with the needs of patients, service providers and payers. Previously untapped potentials in market development must be identified in order to act more successfully.

Homburg & Partner supports medical technology and diagnostic consumer and capital goods suppliers on a global level with dedicated teams specialized in the industry. We advise listed and medium-sized companies as well as start-ups. We have many years of experience and excellent expertise in medical technology, especially in the following key areas:

In the medical technology sector, Homburg & Partner distinguishes between the following three segments:

Homburg & Partner has been advising providers of in-vitro (e.g. high-throughput equipment, point-of-care testing or patient self-testing) and in-vivo diagnostics (e.g. CRT, MRI or X-ray equipment) solutions for diagnosing the state of health of patients for more than ten years.

Whether endoscopes, surgical devices or respiration technologies – nationally and internationally active manufacturers of medical devices profit from their cooperation with Homburg & Partner through exclusive market insights.

Manufacturers of components with lower technical characteristics such as consumables for outpatient and hospital care have trusted Homburg & Partner for decades.

Our experts for medical technology

Porträtbild von Michael Scholl
Managing Director & Partner

Dr. Michael Scholl

michael.scholl@homburg-partner.com
Tel.: +49 621 1582-0

Porträtbild unseres Partners Karl-Hubertus Gruber
Partner

Karl-Hubertus Gruber

karl-hubertus.gruber@homburg-partner.com
Tel.: +49 211 598929-59

Porträtbild von Michael Marquardt
Principal

Dr. Michael Marquardt

michael.marquardt@homburg-partner.com
Tel.: +49 621 1582-148

Medical Technology |  Current topics

Rissige Gesteinsplatten mit Spalten, aus denen orange Lava hervorschimmert

Breaking through the sales plateau in 3 stages

In the US most medium-sized in-vitro-diagnostic (IVD) companies are confronted with a growth hurdle when the sales of their introductory products begin to plateau. This may be a result of changing customer needs, first competitors’ reactions or simply of products having reached their natural revenue peak in the US. To overcome this critical hurdle, companies have to quickly adapt their strategy to the new situation in terms of a market growth perspective. In numerous growth projects, we developed a how-to for midsize IVD companies in order to overcome their most critical growth hurdle.

Boosting Clinical Sales Thumb

Boosting That Bottom Line: Three Portfolio Pricing Tricks

Increasing the price of your product constitutes one of the most direct ways to enhance profits, turning them into an effective means to improve the bottom line in the short term: Profit gains resulting from price increases are not only exempt from any additional costs, but they become almost immediately visible in a company’s financial reports. In this article, Karl-Hubertus Gruber and Michael Marquardt from Homburg & Partner reveal three techniques medtech companies can use to hike their profits.

Quo Vadis In Vitro Diagnostics?

The in vitro diagnostics industry is expected to undergo a transformation. Learn more about the potential disruptors and what IVD companies can do to keep pace.